Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q2 2022 · 10-Q
Revenue$7.40M$7.40M−33.7% vs Q2 2021 Net Income-$3.94M-$3.94MN/M vs Q2 2021 EPS Diluted-$0.93-$0.93N/M vs Q2 2021 Gross Profit$3,830,000−28.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,918,000N/M Free Cash Flowderived-$2,985,000— Margins · derivedGross margin51.8%+3.8 pt vs Q2 2021
Operating margin-25.9%+0.2 pt vs Q2 2021
Net margin-53.3%−22.4 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 15, 2022 · 46 d after period end